In-Med AI unveils Oncoshield – CT for liver pancreas cancer care
IMT News Desk
The product distinguishes between benign and malignant liver lesionsIn-Med AI has launched 'Oncoshield' CT tool for clinical decision support in diagnosing and treating liver and pancreatic cancers. In-Med is a proven leader in developing AI/ML tools for multimodal analytics and radiology in the healthcare field.In-Med Oncoshield software automatically detects and quantifies lesions in the liver and pancreas in CT scans. It automatically calculates volumes and identifies the locations of lesions. This significantly enhances diagnostic capabilities and improves patient care, especially in preparing for surgery. These insights are produced with over 90 per cent accuracy and speedily in a matter of minutes.Oncoshield provides valuable information for treatment planning. It can help surgeons understand the location, size, and characteristics of lesions, aiding in decision-making for the best course of action. By identifying lesions early, Oncoshield can help clinicians better stratify patients based on their risk, allowing for more personalised treatment plans.In-Med’s Oncoshield can reduce radiologist workload through automated analysis and allows healthcare professionals such as oncologists and hepatologists to assess the effectiveness of treatments and make necessary adjustments longitudinally using quantitative measures over time. While final diagnosis and treatment decisions should always involve human healthcare professionals, these AI tools can be an invaluable help to radiologists and other clinicians in giving the best possible care to their patients on a timely basis.The product is currently deployed at the Madras Medical College and the company is offering a 30-day free trial to prospective customers and 90-day free trials to its current customers who may be using Neuroshield.Rahim Pathan, In-Med’s Head of Development Center, said, “At In-Med, innovation is our compass, guiding us toward a future where healthcare is smarter, more accessible, and more compassionate. Our commitment extends beyond mere software development; we are dedicated to pioneering transformative solutions that revolutionise healthcare, one breakthrough after another.”Dr Latha Poonamallee, Founder and CEO, In-Med, added, “At In-Med AI, our mission is to capture the untapped potential of AI in healthcare by leveraging multimodal data across the globe. Our solutions are tailored to each individual with a commitment to inclusion and innovation. Together, we can empower the healthcare ecosystem, save radiologists’ time, and produce more precise and more accurate results faster. Our technology empowers healthcare providers to reach all their patients equally. At the same time, we’re accelerating the availability of accurate data for more precise and faster treatment. And we’re elevating the way that providers treat patients so they can focus on impactful, preventative care. I am excited to continue to expand the scope of our contribution to this field.”The product follows the Neuroshield MRI Volumetry product targeting neurodegenerative conditions like dementia, Alzheimer's, Parkinson's, and Epilepsy and Neuroshield CT TBI products are already operational in over 280 sites in India, Africa and the Middle East. Neuroshield MRI Volumetry recently received the US FDA 510 clearance for sale in the US market. With this new product, In-Med has proven its capacity to expand the applications of its multi-modal and multi-organ capabilities.
